Compare · BDX vs SI
BDX vs SI
Side-by-side comparison of Becton Dickinson and Company (BDX) and Shoulder Innovations Inc. (SI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 111.2x SI ($464.7M).
- Over the past year, BDX is down 2.2% and SI is up 46.4% - SI leads by 48.6 points.
- SI has been more active in the news (15 items in the past 4 weeks vs 10 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Shoulder Innovations Inc.
- Price
- $189.79-0.43%
- $21.96-0.99%
- Market cap
- $51.69B
- $464.7M
- 1M return
- +19.45%
- +3.88%
- 1Y return
- -2.22%
- +46.40%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 15
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Shoulder Innovations Inc.
Silvergate Capital Corporation operates as a bank holding company for Silvergate Bank that provides banking products and services to business and individual clients in the United States and internationally. The company accepts deposit products, including interest and noninterest bearing demand accounts, money market and savings accounts, and certificates of deposit accounts. Its loan products comprise one-to-four family real estate loans, multi-family real estate loans, commercial real estate loans, construction loans, commercial and industrial loans, mortgage warehouse loans, and reverse mortgage loans, as well as consumer loans and other loans secured by personal property. The company also provides cash management services for digital currency-related businesses. The company was founded in 1988 and is headquartered in La Jolla, California.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest SI
- Large owner Gilde Healthcare Holding B.V. sold $567,411 worth of shares (25,097 units at $22.61) (SEC Form 4)
- Chief Operating Officer Ahearn Matthew Fraser gifted 2,500 shares and sold $464,805 worth of shares (22,500 units at $20.66) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 244,176 units (SEC Form 4)
- SEC Form EFFECT filed by Shoulder Innovations Inc.
- New insider Osborne Jonathan E. claimed ownership of 60,355 shares (SEC Form 3)
- Shoulder Innovations Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer
- Amendment: SEC Form SCHEDULE 13D/A filed by Shoulder Innovations Inc.
- Large owner Gilde Healthcare Holding B.V. sold $213,479 worth of shares (9,433 units at $22.63) (SEC Form 4)
- SEC Form S-3 filed by Shoulder Innovations Inc.
- SEC Form 10-Q filed by Shoulder Innovations Inc.